Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Allogene Therapeutics, Inc.NASDAQ: ALLO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$39.44M, compared with -$56.48M a year earlier. Trailing-twelve-month EBITDA was -$160.41M.
Context
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of -$120.06M (+32.3%) for the fiscal year ending Dec 2026, a step up from the +27.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.44M-11.3% QoQ
- Last fiscal yearDec 2025
- -$177.45M+27.1% YoY
- LTMMar 2026
- -$160.41M+32.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.2% | -18.4% | -48.6 pp |
| 1 year | +27.1% | +32.3% | +5.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (177.45M) USD
- Year-over-year change
- +27.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (177.45M) | +27.1% |
| FY2024 | 2024-12-31 | (243.33M) | +22.3% |
| FY2023 | 2023-12-31 | (313.07M) | +4.0% |
| FY2022 | 2022-12-31 | (326.12M) | -90.0% |
| FY2021 | 2021-12-31 | (171.6M) | — |
EBITDA vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's LTM Mar 2026 EBITDA of -$160.41M is the 8th highest of the 9 companies compared; the peer median is -$83.76M.
- Its year-over-year change of +32.7% is the highest of 9, against a peer median of -27.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.48M | +4.6% | — | 23.7% | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$51.11M | -57.3% | — | 75.1% | |
| LTM Dec 2025 | -$77.62M | -86.2% | — | 292.4% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
| Peer median (excluding ALLO) | -$83.76M | -27.0% | — | 249.3% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 114.09M | 156K | 95K | 22K | 0 |
| Cost of Revenue | 0 | 14.3M | 0 | 0 | 12.36M |
| Gross Profit | 114.09M | (14.14M) | 95K | 22K | (12.36M) |
| Gross Margin | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| Research & Development | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| Selling, General & Admin | 74.11M | 79.31M | 71.67M | 65.21M | 56.78M |
| Operating Expenses | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| EBITDA | (171.6M) | (326.12M) | (313.07M) | (243.33M) | (177.45M) |
| EBITDA Margin | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — |
| Operating Income | (180.19M) | (335.54M) | (327.74M) | (273.2M) | (206.93M) |
| Operating Margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Interest Income | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M |
| Interest Expense | 0 | 0 | 0 | 181K | 1.08M |
| Other Income / Expenses | (1.86M) | (4.88M) | 472K | 16.05M | 16.05M |
| Income Before Tax | (182.05M) | (340.41M) | (327.27M) | (257.15M) | (190.89M) |
| Pre-Tax Margin | -159.6% | -218214.1% | -344489.5% | -1168850.0% | — |
| Income Tax Expense | 0 | 0 | 0 | 443K | 0 |
| Net Income | (182.05M) | (340.41M) | (327.27M) | (257.59M) | (190.89M) |
| Net Margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (Basic) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| EPS (Diluted) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| Weighted Avg Shares | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Weighted Avg Shares (Diluted) | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.